<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03548506</url>
  </required_header>
  <id_info>
    <org_study_id>SANTOP</org_study_id>
    <nct_id>NCT03548506</nct_id>
  </id_info>
  <brief_title>Subthalamic Steering for Therapy Optimization in Parkinson's Disease</brief_title>
  <acronym>SANTOP</acronym>
  <official_title>Subthalamic Steering for Therapy Optimization in Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Twenty patients with idiopathic Parkinson's disease (PD) will be included into this single
      center randomized controlled double-blind clinical trial (RCT) in a cross-over design. The
      treatment consists of two different stimulation settings using (i) conventional
      omnidirectional stimulation of the subthalamic nucleus [STN_O] as active comparator and (ii)
      directional steering of STN stimulation via a segmented electrode contact [STN_D].
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty PD patients will be enrolled in this cross-over double-blind RCT to evaluate both the
      safety and efficacy of directional STN stimulation [STN_D] compared with standard
      omnidirectional STN stimulation [STN_O]. The primary outcome measure is objectively
      quantified muscle rigidity of the upper extremity, i.e., surface EMG recordings of the biceps
      and triceps muscle during standardized extension/flexion of the elbow joint (Levin et al.,
      2009) assessed 6 months after implantation in cross-over design. The trial is designed to
      detect with an 80% power a change of 0.27 mA of the therapeutic stimulation threshold with
      two-tailed P &lt; 0.05 (Wilcoxon rank sum test). Secondary outcome measures address clinical
      motor, non-motor, neurocognitive and neuropsychiatric symptoms, freezing of gait, and quality
      of life. Visits are scheduled at weeks 1 (V1), 6 (V2), 24 (V3), 27 (V4), and 30 (V5) from
      baseline (V0).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 19, 2018</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle Rigidity</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Surface-Electromyography (EMG) of M. biceps brachii and M. triceps brachii</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical motor and non-motor symptoms (1)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>MDS-UPDRS I</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical motor and non-motor symptoms (2)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>MDS-UPDRS II</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical motor and non-motor symptoms (3)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>MDS-UPDRS III</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical motor and non-motor symptoms (4)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>MDS-UPDRS IV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical motor and non-motor symptoms (5)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Bradykinesia evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical motor and non-motor symptoms (6)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Tremor evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical motor and non-motor symptoms (7)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Deep brain stimulation impairment scale (DBS-IS):
the scale consists of 22 questions and 6 subscales;
subscales: 1. postural instability and gait difficulties (range 0-20), 2. cognitive impaiment (range 0-20), 3. speaking problems (range 0-12), 4. apathy (range 0-12), 5. impulsivity (range 0-12), and 6. difficulties related to DBS device (range 0-12);
Ʃ 1-6 DBS-IS total range: 0-88;
Ʃ 1-5 DBS-IS total range: 0-76;
higher values represent worsening of symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical motor and non-motor symptoms (8)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Clinical global impression self</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive and non-motor symptoms (1)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Modulation range</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive and non-motor symptoms (2)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Spatial with a visual Odd-Ball test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive and non-motor symptoms (3)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Verbal Working Memory with an auditory Odd-Ball test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive and non-motor symptoms (4)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Power of Attention (Cognitive Drug Research Battery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive and non-motor symptoms (5)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Digit Vigilance Accuracy (Cognitive Drug Research Battery)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive and non-motor symptoms (6)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Executive functions with One Touch Tower of London (Cambridge Neuropsychological Test Automated Battery, CANTAB)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive and non-motor symptoms (7)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Montreal Cognitive Assessment (MoCA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric symptoms (1)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Beck Depression Inventory (BDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychiatric symptoms (2)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Apathy Scale/Lille Apathy rating scale/Neuropsychiatric inventory</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freezing of gait (1)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Capsit-PD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freezing of gait (2)</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Freezing of Gait Assessment Course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months post-operatively</time_frame>
    <description>Parkinson's Disease Questionaire (PDQ-39)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Electroencephalography</measure>
    <time_frame>up to 6 months post-operatively</time_frame>
    <description>Electroencephalography (EEG)</description>
  </other_outcome>
  <other_outcome>
    <measure>Electromyography</measure>
    <time_frame>up to 6 months post-operatively</time_frame>
    <description>Electromyography (EMG)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>STN_O</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Omnidirectional Deep Brain Stimulation of STN</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STN_D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Directional Deep Brain Stimulation of STN</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Omnidirectional Deep Brain Stimulation of STN</intervention_name>
    <description>Deep Brain Stimulation</description>
    <arm_group_label>STN_O</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Directional Deep Brain Stimulation of STN</intervention_name>
    <description>Deep Brain Stimulation</description>
    <arm_group_label>STN_D</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Idiopathic Parkinson's disease (according to the &quot;British Brain Bank criteria&quot;
             (Hughes, 1992) including genetic forms

        Exclusion Criteria:

          -  Cognitive impairment (Mini Mental State Exam &lt; 20)

          -  Suicidality, Psychosis

          -  Other severe pathological chronic condition that might confound treatment effects or
             interpretation of the data

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alireza Gharabaghi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Functional and Restorative Neurosurgery, Department of Neurosurgery, Tuebingen, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Weiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department for Neurodegenerative Diseases, Centre for Neurology, Tuebingen, Germany, and Hertie-Institute for Clinical Brain Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alireza Gharabaghi, MD</last_name>
    <phone>+49707129</phone>
    <phone_ext>85197</phone_ext>
    <email>alireza.gharabaghi@uni-tuebingen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Weiss, MD</last_name>
    <phone>+49707129</phone>
    <phone_ext>82340</phone_ext>
    <email>daniel.weiss@uni-tuebingen.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Tuebingen, Dep. of Neurosurgery (Functional Neurosurgery) and Neurology (Neurodegenerative Diseases)</name>
      <address>
        <city>Tuebingen</city>
        <state>Baden-Wuerttemberg</state>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alireza Gharabaghi, MD</last_name>
      <phone>+49707129</phone>
      <phone_ext>85197</phone_ext>
      <email>alireza.gharabaghi@uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Daniel Weiss, MD</last_name>
      <phone>+49707129</phone>
      <phone_ext>82340</phone_ext>
      <email>daniel.weiss@uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Alireza Gharabaghi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Levin J, Krafczyk S, Valkovic P, Eggert T, Claassen J, Bötzel K. Objective measurement of muscle rigidity in Parkinsonian patients treated with subthalamic stimulation. Mov Disord. 2009 Jan 15;24(1):57-63. doi: 10.1002/mds.22291.</citation>
    <PMID>18855925</PMID>
  </reference>
  <verification_date>June 2018</verification_date>
  <study_first_submitted>April 18, 2018</study_first_submitted>
  <study_first_submitted_qc>June 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>June 8, 2018</last_update_submitted>
  <last_update_submitted_qc>June 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Tuebingen</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Alireza Gharabaghi</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>STN</keyword>
  <keyword>DBS</keyword>
  <keyword>steering</keyword>
  <keyword>segmented electrode leads</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

